Article

Targeting RRM2 Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells

2026-06-18

Abstract excerpt

<title>Abstract</title> <p> Poly(ADP-ribose) polymerase inhibitors (PARPi) have demonstrated clinical efficacy in ovarian cancers with homologous recombination deficiency. However, the therapeutic benefit remains limited in a broader patient population. Ribonucleotide reductase regulatory subunit M2 (RRM2) is a key enzyme controlling deoxyribonucleotide triphosphates (dNTPs) synthesis required for DNA replicatio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f7fb5a02-9685-5462-b2a3-1560ea06cfe5
DOI: 10.21203/rs.3.rs-9819380/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting RRM2 Enhances PARP Inhibitor Efficacy in Ovarian Cancer CellsDOI 10.21203/rs.3.rs-9819380/v1Read

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerSemantic proximity Read

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA MutationsSemantic proximity Read

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerSemantic proximity Read

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalSemantic proximity Read

HIF‐1α‐induced long noncoding RNA LINC02776 promotes drug resistance of ovarian cancer by increasing polyADP‐ribosylationSemantic proximity Read

PARP inhibitors in ovarian cancerSemantic proximity Read

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell linesSemantic proximity Read

JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.Semantic proximity Read

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?Semantic proximity Read